Billing and Coding: MolDX: Oncotype DX® Colon Cancer Assay Update

The Oncotype DX Colon Cancer Assay (CPT 81525) is described for predicting recurrence risk in patients with Stage II colon cancer; claims must use CPT 81525 and report '1' in the Days/Unit. Claims must include the appropriate DEX Z-Code adjacent to the CPT code (specific placement depends on Part A vs Part B and electronic vs paper claim), and an appropriate ICD‑10‑CM diagnosis code must be reported; the policy text does not list specific ICD‑10 codes or broader coverage/exclusion details.

"Oncotype DX Colon Cancer Assay is intended to predict recurrence risk for patients with Stage II colon cancer."

Sign up to see full coverage criteria, indications, and limitations.